Colossal Biosciences
Colossal Biosciences Raises $120M in Series
Colossal Biosciences Raises $120M in Series
Colossal Biosciences has successfully raised $120M in a Series at a $800M valuation led by CIA In-Q-Tel, Breyer Capital.
Company Overview
Colossal Biosciences is a Biotech company headquartered in Austin, TX, founded in 2021 with 100+ employees.
Working on de-extinction of species including mammoths and dodos
Fundraising Details
- Amount Raised: $120M
- Round Type: Series
- Valuation: $800M
- Date: 2025-09-27
- Investors: CIA In-Q-Tel, Breyer Capital
About Colossal Biosciences
Working on de-extinction of species including mammoths and dodos The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Austin, TX
- Founded: 2021
- Team Size: 100+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in Colossal Biosciences's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Colossal Biosciences's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $800M valuation marks an important milestone for Colossal Biosciences, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, Colossal Biosciences is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2025-09-27. For more information about Colossal Biosciences, visit their headquarters at Austin, TX.
Company Info
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free